RxDoctor Payments DataLook up a doctor →

Amit Dande, MD

Interventional Cardiology · Decatur, ILNPI 1477735298

Payments from drug & device makers

$102,064in general payments, 2019–2025

Across 469 payments — averaging $217.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$80K
  • Novartis$8K
  • Lilly USA, LLC$7K
  • Medtronic$2K
  • Novo Nordisk$766
  • Johnson & Johnson$686
  • plus $3K from 34 others

What the payments were for

  • Consulting fees$6,0356%
  • Speaking & faculty fees$84,05682%
  • Travel & lodging$3,8614%
  • Food & beverage$8,1078%
  • Education$50%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$102,064 in reported general payments places this provider in the 85th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$331,147
Medicare patients
1,066
Services billed
3,401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin463$517,671
VyndamaxTafamidis13$349,083
MounjaroTirzepatide247$278,389
EliquisApixaban312$267,164
EntrestoSacubitril/Valsartan190$234,287
XareltoRivaroxaban212$215,527
FarxigaDapagliflozin Propanediol107$114,262
OzempicSemaglutide109$108,149
SynjardyEmpagliflozin/Metformin Hcl78$85,557
BrilintaTicagrelor66$47,359
Repatha SureclickEvolocumab51$41,859
Praluent PenAlirocumab37$33,918
Repatha SyringeEvolocumab34$29,776
VerquvoVericiguat26$26,554
NexletolBempedoic Acid40$23,683

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$172$616,246325 claims
Boehringer IngelheimJardiance, Synjardy$80,035$603,228541 claims
Lilly USA, LLCMounjaro, Trulicity$7,005$294,926265 claims
NovartisEntresto$8,342$234,287190 claims
Johnson & JohnsonXarelto$686$215,527212 claims
AstraZenecaFarxiga, Brilinta$287$161,620173 claims
Novo NordiskOzempic$766$108,149109 claims
Esperion Therapeutics, Inc.Nexletol, Nexlizet$60$36,81963 claims
MerckVerquvo, Belsomra$420$31,27237 claims
Lexicon Pharmaceuticals, Inc.Inpefa$336$19,73629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Decatur

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →